Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tuscold is a multi-ingredient combination medication developed by Med Manor Organics for the symptomatic relief of the common cold, flu, and upper respiratory allergies. It is formulated in various dosage forms, including oral tablets, syrups, and nasal sprays. The standard oral formulations typically combine paracetamol (an analgesic and antipyretic), phenylephrine (a nasal decongestant), and an antihistamine such as chlorpheniramine maleate or cetirizine, sometimes supplemented with zinc gluconate or sodium citrate. Together, these active ingredients work synergistically to reduce fever, alleviate body aches and headaches, relieve nasal congestion and sinus pressure, and control allergic symptoms like runny nose, sneezing, and watery eyes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Tuscold.